Veytics Intelligence
2026-11-09 · NASDAQ

Why ImmunityBio Stock Dropped 15% After Earnings Despite 53% Sales Growth. Is IBRX Now a Buy?

Bản dịch chưa sẵn sàng. Đang hiển thị bài viết gốc.

Key PointsImmunityBio's quarterly product sales rose 53% from a year earlier, but they slipped from the prior quarter and missed Wall Street's estimate.

Doc ban tin day du cua Veytics

Chung toi hien cong khai y chinh. Tao tai khoan mien phi de doc toan bo bai viet, luu, thao luan va ket noi voi boi canh thi truong va OSINT.